StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)

Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –

ImmuCell gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

ImmuCell's gross profit for the twelve months ending Jun 30, 2026 was $12.37M, up 16.8% year over year. For fiscal 2025 it was $11.45M, up 44.1% from the year before. Over ten years it grew 6.2% a year on average. The highest annual figure on record is $11.45M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.45M+44.1%
FY2024Dec 31, 2024$7.94M+105.2%
FY2023Dec 31, 2023$3.87M-49.4%
FY2022Dec 31, 2022$7.65M-11.6%
FY2021Dec 31, 2021$8.66M+26.1%
FY2020Dec 31, 2020$6.86M+1.8%
FY2019Dec 31, 2019$6.74M+29.8%
FY2018Dec 31, 2018$5.19M-0.5%
FY2017Dec 31, 2017$5.22M-3.7%
FY2016Dec 31, 2016$5.42M-13.3%
FY2015Dec 31, 2015$6.25M+40.5%
FY2014Dec 31, 2014$4.45M+45.4%
FY2013Dec 31, 2013$3.06M+0.2%
FY2012Dec 31, 2012$3.05M+8.5%
FY2011Dec 31, 2011$2.81M+22.2%
FY2010Dec 31, 2010$2.30M-4.0%
FY2009Dec 31, 2009$2.40M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.44M-13.5%
Q1 FY2026Mar 31, 2026$4.66M+38.9%
Q4 FY2025Dec 31, 2025$2.91M+2.8%
Q3 FY2025Sep 30, 2025$2.36M+49.2%
Q2 FY2025Jun 30, 2025$2.82M+129.0%
Q1 FY2025Mar 31, 2025$3.35M+46.1%
Q4 FY2024Dec 31, 2024$2.83M–
Q3 FY2024Sep 30, 2024$1.58M+25.0%
Q2 FY2024Jun 30, 2024$1.23M+17.9%
Q1 FY2024Mar 31, 2024$2.30M+663.1%
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$1.27M-31.4%
Q2 FY2023Jun 30, 2023$1.04M-38.9%
Q1 FY2023Mar 31, 2023$300.78K-90.3%
Q4 FY2022Dec 31, 2022$992.18K-61.3%
Q3 FY2022Sep 30, 2022$1.85M-23.7%
Q2 FY2022Jun 30, 2022$1.71M-17.7%
Q1 FY2022Mar 31, 2022$3.10M+93.7%
Q4 FY2021Dec 31, 2021$2.56M+58.0%
Q3 FY2021Sep 30, 2021$2.42M+40.4%
Q2 FY2021Jun 30, 2021$2.07M+61.6%
Q1 FY2021Mar 31, 2021$1.60M-28.3%
Q4 FY2020Dec 31, 2020$1.62M-11.8%
Q3 FY2020Sep 30, 2020$1.72M+18.7%
Q2 FY2020Jun 30, 2020$1.28M+2.8%
Q1 FY2020Mar 31, 2020$2.24M+1.6%
Q4 FY2019Dec 31, 2019$1.84M+31.6%
Q3 FY2019Sep 30, 2019$1.45M+52.6%
Q2 FY2019Jun 30, 2019$1.25M-16.0%
Q1 FY2019Mar 31, 2019$2.20M+61.9%
Q4 FY2018Dec 31, 2018$1.40M+15.2%
Q3 FY2018Sep 30, 2018$950.97K+1.6%
Q2 FY2018Jun 30, 2018$1.49M+61.4%
Q1 FY2018Mar 31, 2018$1.36M-36.8%
Q4 FY2017Dec 31, 2017$1.21M-0.5%
Q3 FY2017Sep 30, 2017$935.85K-22.3%
Q2 FY2017Jun 30, 2017$921.35K–
Q1 FY2017Mar 31, 2017$2.15M–
Q4 FY2016Dec 31, 2016$1.22M–
Q3 FY2016Sep 30, 2016$1.20M–

More ImmuCell figures

See a number that looks wrong?